The increasing importance of speed to clinic puts pressure on biotherapeutics product development timelines.
In this webinar, we discuss how Lonza guarantees* 5 months from DNA to tox drug substance and 11 months to IND with its Ibex® Design 2.0 program.
Using state of the art cloning and expression technologies and running workstream activities in parallel through an integrated services approach enables us to reduce timelines without increasing development risks. The combination of host cell line, vector and stringency of selection enables us to provide our customers with high producing cell lines suited to fit a commercially relevant process.
Our subject matter experts in cell line, process and drug product development walk you through the details and supporting data about how the convergence of technological innovations and over 35 years of track record can deliver speed without compromise.